Altimmune (NasdaqGM:ALT) Q3 2025 Earnings Call November 06, 2025 08:30 AM ET Speaker0In the ongoing regulatory conversation, the statistical significance achieved across a panel of NITs we are assessing in the IMPACT trial provides strong support for pemvidutide anti-fibrotic effects, which we will look to continue to assess in the upcoming 48-week readout. Speaking of the 48-week readout, we look forward to assessing the data and the potential of a longer treatment duration on NIT measurements, as well as ...